Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Melanoma

Head and Neck Neoplasms

Lung Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Pembrolizumab

Antibodies

Antibodies, Monoclonal

Dostarlimab

Immunoglobulins

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Participants will receive EOS-448 and pembrolizumab at every cycle

Participants will receive EOS-448 at every cycle and inupadenant on an ongoing basis

Participants will receive EOS-448 and dostarlimab at every cycle

Participants will receive dostarlimab at every cycle and inupadenant on an ongoing basis

Participants will receive EOS-448 and dostarlimab at every cycle and inupadenant on an ongoing basis

Participants with 1L mNSCLC will receive EOS-448 and dostarlimab and chemotherapies at every cycle

Participants with 1L mHNSCC CPS ≥ 20 will receive EOS-448 and dostarlimab at every cycle

Participants with 1L mHNSCC 1 \< CPS \< 20 will receive EOS-448 and dostarlimab at every cycle

EOS-448

pembrolizumab

inupadenant

SOC chemotherapies

iTeos Belgium SA

Clinical Trial Unit

Clinical Trial Unit Unit

Clinical Trials Unit

Iteos Clinical Trials

This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.

The combinations evaluated will be:

* EOS-448 combined with pembrolizumab, an anti-PD-1 antibody
* EOS-448 combined with inupadenant an investigational adenosine A2A receptor antagonist
* EOS-448 combined with dostarlimab an anti-PD-1 antibody
* inupadenant combined with dostarlimab
* EOS-448 combined with inupadenant and dostarlimab
* EOS-448 combined with dostarlimab and standard of care chemotherapies in participants with NSCLC

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

A Multicenter, Open-Label, Phase I/II Study of EOS884448 (EOS-448) in Combination With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Spots Global Cancer Trial Database for a2a receptor antagonist